PNC-27 (10mg)

Description

PNC-27 is an 18-amino acid research peptide derived from the p21WAF1/CIP1 MDM2-binding domain, designed to interact with MDM2 (Mouse Double Minute 2) when it is expressed on cancer cell plasma membranes — a phenomenon selectively observed in transformed cells but not normal cells. This selective targeting of MDM2-expressing cancer cells has made PNC-27 a subject of investigation in oncology research as a potential cancer cell-selective pro-apoptotic tool compound.

Why Researchers Select PNC-27

MDM2 overexpression is a common feature of many cancer types and normally functions to ubiquitinate p53, targeting it for proteasomal degradation. In a subset of cancer cells, MDM2 is aberrantly translocated to the plasma membrane — a feature that normal cells lack. PNC-27 contains both an MDM2-binding domain and a membrane-destabilizing sequence; when it binds membrane-localized MDM2, it disrupts membrane integrity specifically in those cancer cells, triggering necrotic cell death. This selectivity profile makes PNC-27 a tool compound for studying cancer cell-specific membrane vulnerability and MDM2 cell-surface biology.

Common Research Applications

• MDM2 cell-surface expression characterization in cancer cell lines
• Cancer cell-selective membrane disruption mechanism studies
• p21-MDM2 interaction and p53 pathway research
• Selective cancer cell apoptosis/necrosis pathway investigation
• MDM2 overexpression tumor model studies

Molecular Profile

• Type: p21-derived MDM2-binding peptide (18 AA) | Purity: ≥95% HPLC | Form: Lyophilized

For Research Use Only. Not for human or veterinary use.